Alpha 1-antitrypsin deficiency

Nov 07, 2019

Grifols introduces AlphaID(TM), a free cheek swab to screen for Alpha-1, the most common genetic form of COPD

Sep 04, 2019

Inhibrx Announces Enrollment of First Patient in Phase 1 Study of INBRX-101, a Modified Recombinant Human AAT-Fc Fusion Protein

Apr 25, 2019

CSL Behring Delivers on its Continued Commitment to Alpha 1 Patients with FDA Approval of Convenient Single-Vial Dosing for ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)]

Nov 01, 2018

Grifols affirms commitment to patients during Alpha-1 Awareness Month

Jul 31, 2018

Alpha-1 Foundation Board Has New Chair

Jan 31, 2018

First John W. Walsh Translational Research Award Granted

Aug 08, 2017

Alpha-1 Antitrypsin Deficiency Treatment Market to Reach US$2,908.1 Million by 2025: Prevalence of Respiratory Diseases Driving Demand

Jun 05, 2017

More Than 600 to Hear Top World Experts on Alpha-1, Genetic Cause of Lung and Liver Disease, at National Conference in Chicago